Latest News & Views in Diabetes Technology

Aspect Biosystems, and Novo Nordisk are collaborating to develop bioprinted tissue therapeutics for the treatment of diabetes and obesity. Novo Nordisk will have an exclusive worldwide license to use Aspect's bioprinting technology to develop up to four products to treat diabetes and/or obesity. The goal of the collaboration is to develop implantable bioprinted tissues that will replace, repair, or supplement biological functions inside the body to deliver a new class of disease-modifying treatments. The collaboration will initially focus on developing bioprinted tissue therapeutics designed to maintain normal blood glucose levels without the need for immunosuppression, which could represent a transformative treatment for people living with type 1 diabetes.

Beginning next week, Medicare will expand coverage of continuous glucose monitors (CGMs) for a broader group of Type 2 diabetes (T2D) patients. The new policy is expected to increase access and decrease health disparities in the diabetes community.

When a person with type 1 diabetes (T1D) gets sick, blood glucose (or sugar) can increase drastically. This can cause the blood to become acidic and lead to diabetes ketoacidosis (or DKA), a dangerous and life-threatening condition that requires immediate medical attention. Our friends at T1D Exchange and the T1D Exchange Quality Improvement Collaborative (T1DX-QI)’s Patient Parent Advisory Committee and physicians have created this Sick Day Management guide for people living with type 1 diabetes to manage their blood glucose when ill and provide tips to prevent DKA.